GlobeNewswire Inc.··Hagens BermanAardvark Therapeutics Stock Crashes 56% on Lead Drug Safety Pause
$AARD plummets 56% after pausing Phase 3 trial for ARD-101 due to cardiac safety concerns, contradicting prior safety assurances.
AARDinvestor lossessecurities fraud investigation